Dr Fiona Douglas
Kate Bailey
| Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes | 2022 |
|
Dr Fiona Douglas
| Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival after Radical Treatment for Localised Prostate Cancer | 2015 |
|
Dr Fiona Douglas
| Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers | 2014 |
|
Dr Fiona Douglas
| Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome | 2014 |
|
Dr Fiona Douglas
| DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers | 2014 |
|
Dr Fiona Douglas
| Lymphocyte Telomere Length Is Long in BRCA1 and BRCA2 Mutation Carriers Regardless of Cancer-Affected Status | 2014 |
|
Professor Neil Rajan
Dr Piotr Pieniazek
Paul Hainsworth
Dr Fiona Douglas
Professor Ruth Plummer
et al. | Mesenteric cysts in Gorlin syndrome: a mimic of metastatic disease | 2014 |
|
Dr Fiona Douglas
Alexander Henderson
Penny Wilson
| Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study | 2014 |
|
Dr Fiona Douglas
| Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk | 2013 |
|
Dr Fiona Douglas
Alexander Henderson
| Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer | 2013 |
|
Professor Kofi Oppong
Dr Paul Brennan
Dr Fiona Douglas
Richard Charnley
| Pancreatic Cancer Screening - are we doing it right? | 2013 |
|
Dr Fiona Douglas
| Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men | 2013 |
|
Dr Fiona Douglas
| Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 | 2012 |
|
Dr Fiona Douglas
| Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers | 2012 |
|
Dr Fiona Douglas
| Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers | 2012 |
|
Dr Fiona Douglas
| Gene-gene interactions in breast cancer susceptibility | 2012 |
|
Dr Fiona Douglas
| Is colorectal surveillance indicated in patients with PTEN mutations? | 2012 |
|
Dr Fiona Douglas
| Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers | 2011 |
|
Dr Fiona Douglas
| Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2 | 2011 |
|
Dr Fiona Douglas
| Exploring the link between MORF4L1 and risk of breast cancer | 2011 |
|
Dr Fiona Douglas
Dr Chris Lord
| Germline mutations in RAD51D confer susceptibility to ovarian cancer | 2011 |
|
Dr Fiona Douglas
| Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer | 2011 |
|
Dr Fiona Douglas
| Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the IMPACT study | 2011 |
|
Dr Elizabeth Jones
Dr Fiona Douglas
Dr Nicholas Bown
| Wilms Tumor Incidence in Children With 2q Terminal Deletions: A Cohort Study | 2011 |
|
Dr Fiona Douglas
Dr Anne-Marie Gerdes
| A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population | 2010 |
|
Dr Fiona Douglas
Professor David Neal
| The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine | 2010 |
|
Dr Fiona Douglas
Dr Stephen Ball
| Tumour risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD | 2010 |
|
Dr John Beesley
Dr Anne-Marie Gerdes
Dr Fiona Douglas
| Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA) | 2009 |
|
Dr Fiona Douglas
Dr Petros Perros
| SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis | 2009 |
|
Dr Anne-Marie Gerdes
Dr Fiona Douglas
| Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers | 2008 |
|
Dr Fiona Douglas
| Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: Validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics | 2008 |
|
Dr Stephen Ball
Dr Fiona Douglas
Professor Thomas Lennard
| Familial endocrine disease: genetics, clinical presentation and management | 2006 |
|
Dr Stephen Ball
Dr Fiona Douglas
Professor Thomas Lennard
| Familial endocrine disease: genetics, clinical presentation and management | 2006 |
|
Professor Sir John Burn
Dr Fiona Douglas
| Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International society for gastrointestinal hereditary tumours collaborative study | 2006 |
|
Dr Rachel Davies
Dr Fiona Douglas
| Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers | 2006 |
|
Dr Fiona Douglas
| A randomised comparison of UK genetic risk counselling services for familial cancer: Psychosocial outcomes | 2004 |
|
Dr Fiona Douglas
| Does cascading work in breast cancer families? A critical audit of BRCA1/BRCA2 mutation carriers and their at risk family members | 2004 |
|
Professor Colin Wilson
Clive Griffith
Dr Jyotsna Shrimankar
Dr Fiona Douglas
| Gynaecomastia, neurofibromatosis and breast cancer | 2004 |
|
Dr Fiona Douglas
| Electronic patient records - implications for genetics | 2003 |
|
Dr Fiona Douglas
Dr Ann Curtis
| Identification of a truncating mutation in the TES gene in a patient with familial ovarian cancer | 2003 |
|
Dr Fiona Douglas
Michelle Watson
Jamie Burn
| A descriptive study of UK cancer genetics services: an emerging clinical response to the new genetics | 2001 |
|
Dr Fiona Douglas
| Consent and Confidentiality: the issues that affect Clinical Genetics and the achievement of good practice in this context | 2001 |
|
Dr Fiona Douglas
| Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma | 2001 |
|
Dr Fiona Douglas
| Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma | 2001 |
|
Dr Fiona Douglas
| Mutations in the mitochondrial complex II subunit SDHB cause susceptibility to familial phaeochromocytoma and paraganglioma | 2001 |
|
Dr Ujjal Mallick
Dr John Fenwick
Dr Robert James
Dr Sarah Johnson
Professor Pat Kendall-Taylor
et al. | Northern cancer network guidelines for management of thyroid cancer | 2000 |
|
Dr Ujjal Mallick
Dr Helen Lucraft
George Proud
Dr Petros Perros
Dr John Fenwick
et al. | Optimizing the management of differentiated thyroid cancer. | 2000 |
|
Dr Fiona Douglas
Dr Sally Lynch
| The accuracy of diagnoses as reported in families with cancer: a retrospective study | 1999 |
|
Dr Fiona Douglas
Dr Sally Lynch
| The accuracy of diagnoses as reported in families with cancer: A retrospective study | 1999 |
|
